mondoBIOTECH holding AG (SIX:RARE): the Board of Directors has set the final terms of its planned capital increase
The share capital increase structured as a rights offering to existing shareholders (the "Rights Offering") of up to 354’038 new registered common shares with a par value of CHF 0.10 each to be issued from the Company's existing authorized share capital, with shares not taken up in the Rights Offering to be placed privately by the Company with selected investors.
- (1888PressRelease) April 05, 2011 - The Board of Directors has, on the basis of the volume-weighted average price on the SIX Swiss Exchange during the trading period between 21 March and 1 April 2011, set the subscription price per offered share at CHF 49.
The Company has received commitments for 164’489 offered shares, corresponding to a total amount of CHF 8’060’000.
The subscription period for existing shareholders is expected to run from 4 April 2011 until 11 April 2011, 12.00 noon (CEST). Ex-rights trading in the existing common shares will start on 4 April 2011. The subscription rights will not be tradable on the SIX Swiss Exchange. Subscription rights not duly exercised will expire without compensation. Shares not taken up in the Rights Offering will be used in the Selected Offering.
Existing shareholders will be allotted 10 subscription rights for each listed common share and 1 subscription right for each non-listed voting right share held after close of trading on the SIX Swiss Exchange on 1 April 2011. 190 subscription rights entitle to subscribe for one new common share at the subscription price of CHF 49. Accordingly, 19 existing common shares and 190 voting right shares, respectively, entitle to subscribe for one new common share. The expected net proceeds from the Offering will be used to continue to fund the Company's growth strategy and for general corporate purposes.
The first trading day of the newly issued common shares on the SIX Swiss Exchange is expected to be 15 April 2011 and delivery of the newly issued shares expected to take place on 18 April 2011. The new common shares will be fully fungible with the existing common shares.
The offered shares are not underwritten. The exact number of common shares to be issued in the Offering therefore depends on the total amount of subscriptions received.
About mondoBIOTECH
mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its internally developed Search&Match methodology. In Search&Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners.
Furthermore, mondoBIOTECH has built and is expanding a continuous growing Community of high-level physicians and researchers who dedicate their life to rare diseases. This Rare Community is made up of biologists, biochemists, physicians, patients and patient advocacy organizations as well as other persons and organizations who share their experiences, know-how, expertise and skills with mondoBIOTECH to reach out to people who will benefit the most from an effective treatment, the patients.
Contact:
mondoBIOTECH holding AG
Investor Relations, Mr. Paolo Bassanini
Das Kloster
Muergstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011
investor ( @ ) mondobiotech dot com
Disclaimer
The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward looking statements contained in this press release as a result of new information, future events or otherwise.
THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. ANY NON-COMPLIANCE WITH SUCH RESTRICTIONS MAY RESULT IN AN INFRINGEMENT OF U.S. SECURITIES LAWS. SECURITIES OF mondoBIOTECH holding AG ARE NOT BEING PUBLICLY OFFERED OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF mondoBIOTECH holding AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT THE REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES LAWS. THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS ACCORDING TO ART. 652A OR ART. 1156 OF THE SWISS CODE OF OBLIGATIONS OR ART. 27 ET SEQ. OF THE LISTING RULES OF SIX SWISS EXCHANGE.
This document is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). The shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this information or any of its contents.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam